公司資料
AEON Biopharma 股價、新聞與催化劑
- 股票代碼:
- AEON
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
0.26 USD (-7.12%)
收盤價
最後更新: 2026年8月17日
19.7M USD
市值
股價為何變動
As of Aug 17, 2026, AEON closed down 7.12% at $0.2555. No new same-company headline was identified in the current news window.
公司概覽
業務概覽
AEON Biopharma is a clinical-stage neurotoxin company focused on botulinum toxin-based therapies and the potential to build a differentiated commercial asset in aesthetics and neurology. The investment case centers on whether the company can turn a highly specialized product profile into a durable franchise.
所在地與產業分類
Headquartered in the United States and listed on NASDAQ, AEON sits in the specialty therapeutics segment. Its profile is shaped more by product execution and regulatory positioning than by broad pipeline breadth.
商業模式特徵
AEON depends on clinical progress, commercialization strategy, and the ability to convert a focused asset base into repeatable revenue. Investors typically watch launch timing, commercial access, and strategic financing decisions.
生技產業定位
AEON sits in a narrow but catalyst-sensitive corner of biotech where a single program can drive most of the valuation. Compared with larger peers, the stock is more exposed to execution risk and inflection-point revaluation.
未來催化劑
- The next three months should center on ABP-450 biosimilar development, especially follow-up with the FDA on the analytical package and the next BPD meeting steps that determine whether the program can stay on a clean regulatory path. The next checkpoint matters because it tells investors whether the program is still moving on schedule or whether the timeline needs to be reset. A clean outcome also makes it easier to think about the next regulatory or label step instead of just the current filing.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。